The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE:LLY) for chronic kidney disease was terminated due to a lack of foreseeable clinical benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback